-
Mashup Score: 2Diet-Derived Metabolite Affects CAR T-Cell Treatment in Mouse Models | ASH Clinical News | American Society of Hematology - 17 day(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. After testing numerous diets, researchers, led by Shan Liu, MD, of the University of Pennsylvania, foun d that a ketogenic diet-derived level of β-hydroxybutyrate (BHB) might augment chimeric antigen receptor (CAR) T-cell function in multiple types of cancer. Dr. Liu will present these findings during a plenary session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. Using a mouse model
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Anna Azvolinsky is a science and health journalist based in New York City. Counseling was identified as the most effective and commonly researched communication tool that clinicians use to discuss reproductive needs with their female patients who have cancer and are of childbearing age. Counseling was shown to provide significant improvements for these women in fertility or sexual dysfunction outcomes. These are the results of an analysis of 14 published studies that reviewed tools that can be best used
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Among #female patients with #cancer who are of #childbearing age, counseling was identified as the most effective and commonly researched communication tool that clinicians use to discuss patients' reproductive health and needs: https://t.co/8YnI8NZ9i8 #ASH24
-
-
Mashup Score: 1Patient Motivators Key for Participation in SCD Clinical Trials | ASH Clinical News | American Society of Hematology - 18 day(s) ago
Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. At a Saturday, December 7 session of the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, Biree Andemariam, MD, a hematologist and founding director of the New England Sickle Cell Institute at the University of Connecticut Health Center, will present findings on different motivators that influence whether people with sickle cell disease (SCD) choose to participate in clinical trials.
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
A recent analysis from the LISTEN survey has shown that how individuals with #SCD rated the importance of motivators, such as better symptom management, had the greatest association with the likelihood of wanting to participate in a clinical trial: https://t.co/zF8V1awhk1 #ASH24
-
-
Mashup Score: 1
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. An analysis of patients with myeloproliferative neoplasms (MPN) has revealed that pulmonary hypertension (PH) is associated with an increased risk of hematologic progression and major adverse cardiovascular events (MACE). Orly Leiva, MD, an advanced heart failure and transplantation fellow at the University of Chicago, will present results that shed light on the pathophysiology behind PH and MPN progression, including an association
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
According to an analysis to be presented at #ASH24, #pulmonary #hypertension was found to be associated with an increased risk of #hematologic progression and major adverse #cardiovascular events in patients with #MPNsm: https://t.co/Vm70G4nDP3
-
-
Mashup Score: 2p53 May Have Role in VEXAS Syndrome | ASH Clinical News | American Society of Hematology - 19 day(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. Researchers have discovered a previously unknown role of p53 in VEXAS syndrome physiopathology, according to research that will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. VEXAS syndrome is an autoinflammatory disorder caused by mutations that occur in the UBA1 gene. Olivier Hermine, MD, PhD, of Necker-Enfants Malades Hospital in Paris, and colleagues hypothesize d that UBA1 -mutated
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
According to research to be presented at #ASH24, p53 may be a key player of #VEXAS syndrome physiopathology, with findings showing that VEXAS-causing UBA1 variants resulted in massive cell death at the early stage of #erythroid differentiation: https://t.co/s9Lx4KvOxZ
-
-
Mashup Score: 3
Leah Lawrence is a freelance health writer and editor based in Delaware. Induction therapy with combination chemotherapy plus gilteritinib yielded an excellent compositive complete remission (CRc) rate with no treatment-related deaths in patients with newly diagnosed FLT3 -mutated acute myeloid leukemia (AML), according to the results of the phase II Precog 0905 study, which will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. However, although gilteritinib
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Induction therapy with #chemotherapy plus #gilteritinib yielded an excellent CRc rate with no treatment-related deaths in patients with newly diagnosed FLT3 #AML but didn’t significantly increase the FLT3-negative CRc rate after induction: https://t.co/RL0bj0B7ga #ASH24
-
-
Mashup Score: 8
Anna Azvolinsky is a science and health journalist based in New York City. Patients with multiple myeloma (MM) receiving autologous B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy who experience immune effector cell-associated hematotoxicity (ICAHT) can be treated effectively and safely with a stem cell boost. This is according to a multicenter study of patients who received the CAR T-cell therapy as part of a clinical trial or commercially available therapy; the study
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
For patients with #MMsm receiving #BCMA CAR #TcellRX who experienced ICAHT, stem cell boosts led to clinically and statistically significant improvements in cell counts at three and six months, indicating they may be a safe and effective treatment #ASH24: https://t.co/oZNXwmZmSg
-
-
Mashup Score: 2
Khylia Marshall is a freelance journalist based in Tucson, Arizona. Currently, various molecular-based prediction models exist to prognosticate overall survival (OS) in patients with chronic myeloproliferative neoplasms (MPN). However, at the 66th American Hematology Society (ASH) Annual Meeting and Exposition, Shivani Handa, MD, of the Division of Hematology at The Ohio State University Wexner Medical Center in Columbus, will present findings showing that TP53 alterations (TP53+) have a stronger associati
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
New findings from #ASH24 indicate that #TP53 alterations play a significant role in #MPNsm disease progression, with a stronger association with OS and risk of leukemic progression than previously validated HMR mutations: https://t.co/556SwehKiR
-
-
Mashup Score: 4
December 2024 | ASH Clinical News | American Society of Hematology December 2024 Superhero and Villain Although shows like Supacell bring awareness to sickle cell disease, many media depictions contribute to stereotypes and misinformation. Viewpoints Editor’s Corner A Thousand Milestones to Move Us Forward Book Reviews Toxic Exposure: Into the Weeds of the Monsanto Trials Education You Make the Call…
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
The December issue is out now! Highlights include a feature article on #Netflix's #Supacell and media portrayals of #sicklecelldisease #SCD, efficacy of pegcetacoplan for #ColdAgglutininDisease and #wAIHA, and more. See the full lineup here: https://t.co/kQYcCw4jz0 https://t.co/tek2wBFklm
-
-
Mashup Score: 1CLL Precursor Condition Linked with Melanoma Risk | ASH Clinical News | American Society of Hematology - 25 day(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. Individuals diagnosed with low-count monoclonal B-cell lymphocytosis (LC-MBL) had about a two-fold increased risk for melanoma, similar to that seen in individuals with chronic lymphocytic leukemia (CLL), a study published in the Journal of Clinical Oncology found. Melanoma is one of the most common second primary malignancies diagnosed in patients with CLL. In this study, Susan L. Slager, PhD, of Mayo Clinic in Rochester, Minnesota,
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
According to a recent study, individuals with #ChronicLymphocyticLeukemia and its precursor condition, low-count monoclonal B-cell #lymphocytosis, are at similar risk for #melanoma, with about a two-fold increased risk in both groups: https://t.co/LKvfer7HAa
-
A #ketogenic diet may augment CAR T-cell function in multiple types of #cancer, as mice infused with anti-CD19 CAR T cells who were fed such a diet had improved #tumor control and overall survival compared with other tested diets: https://t.co/ppIGCbaHKu #ASH24